B
Brian Dougherty
Researcher at AstraZeneca
Publications - 75
Citations - 25953
Brian Dougherty is an academic researcher from AstraZeneca. The author has contributed to research in topics: Olaparib & Genome. The author has an hindex of 35, co-authored 67 publications receiving 24290 citations. Previous affiliations of Brian Dougherty include Johns Hopkins University School of Medicine & J. Craig Venter Institute.
Papers
More filters
Journal ArticleDOI
Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial
Darren Hodgson,Jessica S Brown,Simon Dearden,Zhongwu Lai,Cathy E. Elks,Tsveta Milenkova,Brian Dougherty,Jerry S. Lanchbury,Michael C. Perry,Kirsten Timms,Elizabeth A. Harrington,J. Carl Barrett,Alexandra Leary,Eric Pujade-Lauraine +13 more
TL;DR: Very high concordance was demonstrated between tumor and germline BRCA testing, supporting wider implementation of tumor testing in ovarian cancer as mentioned in this paper, which suggests routine testing for BRCa zygosity is not required in this population and reflects BRCAs loss being a driver of tumorigenesis.
Journal ArticleDOI
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Violeta Serra,Anderson T. Wang,Marta Castroviejo-Bermejo,Urszula M. Polanska,Marta Palafox,Andrea Herencia-Ropero,Gemma N. Jones,Zhongwu Lai,Joshua Armenia,Filippos Michopoulos,Alba Llop-Guevara,Rachel Brough,Aditi Gulati,Stephen J. Pettitt,Krishna C. Bulusu,Jenni Nikkilä,Zena Wilson,Adina M. Hughes,Paul Wijnhoven,Ambar Ahmed,Alejandra Bruna,Albert Gris-Oliver,Marta Guzman,Olga Rodriguez,Judit Grueso,Joaquín Arribas,Javier Cortes,Cristina Saura,Alan Lau,Susan E. Critchlow,Brian Dougherty,Carlos Caldas,Gordon B. Mills,J. Carl Barrett,Josep V. Forment,Elaine Cadogan,Christopher J. Lord,Cristina Cruz,Judith Balmaña,Mark J. O'Connor +39 more
TL;DR: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance including tumors without an underlying HRR deficiency.
Journal ArticleDOI
Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC).
Brian Dougherty,Jonathan A. Ledermann,Zhongwu Lai,Jane Robertson,Tony W. Ho,Darren Hodgson,Mark J. O'Connor,Anitra Fielding,Matthew J. Hawryluk,Tim Brennan,Roman Yelensky,James Sun,J. Carl Barrett +12 more
TL;DR: Exploratory characterization of genetic changes in tumors from PSR SOC pts to determine the frequency and co-occurrence patterns of mutations in BRCA1/2 and other HRR genes, and the presence of these mutations in pts with a long-term response (LTR; treatment duration >24 mo).
Proceedings ArticleDOI
Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations inBRCA1orBRCA2are biologically similar and sensitive to PARP inhibition
Brian Dougherty,Zhongwu Lai,Jonathan A. Ledermann,Jane Robertson,Tony W. Ho,Wenting Wu,Darren Hodgson,Maria Orr,Mark J. O'Connor,Matthew J. Hawryluk,Tim Brennan,Roman Yelensky,James Sun,J. Carl Barrett +13 more
TL;DR: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in BRCA1 or BRCa2 are biologically similar and sensitive to PARP inhibition.
Proceedings ArticleDOI
Abstract LB-249: Examination of analytical factors impacting concordance of plasma-tumor testing by next-generation sequencing (NGS)
Daniel Stetson,Brian Dougherty,Ambar Ahmed,Tristan J. Lubinski,Aleksandra Markovets,Kenneth S. Thress,Robert McEwen,Gaia Schiavon,David Whitston,Barrett Nuttall,J. Carl Barrett +10 more
TL;DR: Assay analytical variance and the impact of reporting false positive variants are key factors that need to be addressed as plasma-based NGS testing is more widely incorporated into translational and clinical research.